Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Intuit Inc. (INTU) vs BIO-TECHNE Corp (TECH) Price & Performance

Intuit Inc.Trade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Intuit Inc. vs BIO-TECHNE Corp — how do they compare? Intuit Inc. trades at $302.75 (market cap $81.21B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Intuit Inc. is far larger — about 7.1× BIO-TECHNE Corp's market cap, and Intuit Inc. pays the higher dividend (1.82%). Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 66 Days and BIO-TECHNE Corp for 64 Days on average.

INTUTECH
Market Cap
$81.21B$11.36B
Volume
5,165,8065,390,331
Sector
TechnologyHealth
52-Week High
$683.39$72.61
52-Week Low
$255.07$43.31
Typical Hold Time
66 Days64 Days
Enterprise Value
$82.43B$11.39B
Dividend Yield
1.82%0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Intuit Inc.

Intuit (INTU) trades at $303.88, up 2.23% today, with strong technical momentum as it approaches resistance near $307. The company demonstrates robust fundamentals with revenue growth from $18.83B in 2025 to projected $21.4B in 2026, net margins expanding to 21.29%, and consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $379.68 price target, though recent class action lawsuits create near-term sentiment headwinds.

INTU presents a compelling growth story with strong profitability and market leadership in financial software. The primary investment opportunity lies in continued QuickBooks and TurboTax monetization, while risks include legal overhang from securities litigation and competitive pressures in the fintech space. Current valuation at 18.46 P/E appears reasonable given earnings growth trajectory.

BIO-TECHNE Corp

TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.

The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INTU
25% Buy75% Sell
Avg holding period · 66 Days
TECH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Intuit Inc.

Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.

Read more on INTU →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →